Australia-based genomics-based tests provider Genetic Technologies has launched the geneType Risk Assessment portfolio on its EasyDNA platform.
Established in 2007, EasyDNA is an online provider of genetic testing services that has grown into an online network of more than 70 websites in over 42 countries.
Together with the company’s structural reset, the move is expected to reduce cash burn to less than A$200,000 ($132,000) per month from the previous A$800,000 ($530,000).
Genetic Technologies said the geneType portfolio, offered on the EasyDNA platform will enhance the product’s global access, to realise more than 70% gross margin.
The company believes this is the right time to add geneType to the EasyDNA marketplace in the US, building on successful influencer campaigns and initiatives.
Together with its partners, Nest Genomics, DNA Nexus, DNA Visit, Gene by Gene and Fabric Genomics, Genetic Technologies has built an online process for both clinicians and consumers.
Genetic Technologies, in its statement, said: “Aligned in GENE’s mission to transform the approach to population healthcare on a personalised basis, these partnerships support telehealth-enabled access to clinical testing.
“The placement of the geneType consumer-initiated pipeline on the EasyDNA platform will increase the visibility and reach of the product line while maintaining the required clinical oversight.
“This pipeline enables a uniform operational workflow regardless of specimen origin. All laboratory processing of samples will be carried out through GENE’s laboratory partner Gene By Gene.
“Data analysis, a critical element of GENE’s intellectual property and accreditation status, will remain in our Australian-based laboratory using the company’s cloud-based algorithms allowing GENE to process data in local environments according to local data regulations by country.”
Genetic Technologies launched the new initiative in July this year, which is designed to simplify the completion of the clinical questionnaire and the communication of results.
The company has implemented a user-friendly consumer interface with Nest Genomics, which has expertise in the field of genetic-based, patient-facing communication.
It will harness Nest Genomics’ capabilities to support the post-test continuum of care.
